These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37543629)

  • 41. Acromegaly.
    Scacchi M; Cavagnini F
    Pituitary; 2006; 9(4):297-303. PubMed ID: 17077948
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Subclinical acromegaly: to treat or not to treat?
    Shimon I; Adnan Z; Hirsch D; Duskin-Bitan H; Akirov A
    Endocr J; 2022 Nov; 69(11):1323-1328. PubMed ID: 35732439
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
    Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
    Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Acromegaly. Treatment of the causal factor and the oral sequelae].
    Feelders RA; Delwel EJ; de Baat C
    Ned Tijdschr Tandheelkd; 2004 Jan; 111(1):20-2. PubMed ID: 14768241
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of acromegaly by endoscopic transsphenoidal surgery: surgical experience in 214 cases and cure rates according to current consensus criteria.
    Hazer DB; Işık S; Berker D; Güler S; Gürlek A; Yücel T; Berker M
    J Neurosurg; 2013 Dec; 119(6):1467-77. PubMed ID: 24074496
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Postoperative persistent thyrotrophin releasing hormone-induced growth hormone release predicts recurrence in patients with acromegaly.
    Biermasz NR; Smit JW; van Dulken H; Roelfsema F
    Clin Endocrinol (Oxf); 2002 Mar; 56(3):313-9. PubMed ID: 11940042
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Relationships between insulin-like growth factor-1 levels and growth hormone concentrations during diurnal profiles and following oral glucose in acromegaly.
    Dobrashian RD; O'Halloran DJ; Hunt A; Beardwell CG; Shalet SM
    Clin Endocrinol (Oxf); 1993 Jun; 38(6):589-93. PubMed ID: 8334745
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A case of excess growth hormone levels.
    Shariff M; Dhillo WS; Seal LJ; Todd JF; Meeran K
    Int J Clin Pract Suppl; 2005 Apr; (147):34-6. PubMed ID: 15875616
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dynamic testing in the diagnosis and follow-up of patients with acromegaly.
    Wass JA
    J Endocrinol Invest; 2003; 26(7 Suppl):48-53. PubMed ID: 14604066
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment results of acromegaly as analyzed by different criteria.
    van Lindert E; Hey O; Boecher-Schwarz H; Perneczky A
    Acta Neurochir (Wien); 1997; 139(10):905-12; discussion 912-3. PubMed ID: 9401649
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical, hormonal and magnetic resonance imaging (MRI) predictors of transsphenoidal surgery outcome in acromegaly.
    Bourdelot A; Coste J; Hazebroucq V; Gaillard S; Cazabat L; Bertagna X; Bertherat J
    Eur J Endocrinol; 2004 Jun; 150(6):763-71. PubMed ID: 15191345
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Diagnosis, treatment and follow-up of patients with acromegaly in a clinical practice setting in Spain: the ACROPRAXIS program Delphi survey.
    de Pablos-Velasco P; Venegas EM; Álvarez Escolá C; Fajardo C; de Miguel P; González N; Bernabéu I; Valdés N; Paja M; Díez JJ; Biagetti B
    Pituitary; 2020 Apr; 23(2):129-139. PubMed ID: 31823249
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Acromegaly].
    Chanson P
    Presse Med; 2009 Jan; 38(1):92-102. PubMed ID: 19004612
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ghrelin test for the assessment of GH status in successfully treated patients with acromegaly.
    Pekic S; Doknic M; Miljic D; Joksimovic M; Glodic J; Djurovic M; Dieguez C; Casanueva F; Popovic V
    Eur J Endocrinol; 2006 May; 154(5):659-66. PubMed ID: 16645012
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Acromegaly with 'normal' serum growth hormone levels. Clinical features, diagnosis and results of transsphenoidal microsurgery.
    Brockmeier SJ; Buchfelder M; Adams EF; Schott W; Fahlbusch R
    Horm Metab Res; 1992 Aug; 24(8):392-400. PubMed ID: 1526628
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-Term Effects of Intracapsular Debulking and Adjuvant Somatostatin Analogs for Growth Hormone-Secreting Pituitary Macroadenoma: 10 Years of Experience in a Single Institute.
    Shen SC; Shen CC; Pu TW; Cheng WY
    World Neurosurg; 2019 Jun; 126():e41-e47. PubMed ID: 30716503
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Successful treatment of pituitary gigantism.
    Cunha C; Saraiva C; Canas Marques C; Duarte JS
    BMJ Case Rep; 2021 Dec; 14(12):. PubMed ID: 34972788
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure.
    Sheaves R; Jenkins P; Blackburn P; Huneidi AH; Afshar F; Medbak S; Grossman AB; Besser GM; Wass JA
    Clin Endocrinol (Oxf); 1996 Oct; 45(4):407-13. PubMed ID: 8959078
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A multihormonal pituitary adenoma with growth hormone and adrenocorticotropic hormone production, causing acromegaly and Cushing disease.
    Kageyama K; Nigawara T; Kamata Y; Terui K; Anzai J; Sakihara S; Suda T
    Am J Med Sci; 2002 Dec; 324(6):326-30. PubMed ID: 12495300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.